ArticleCommunications biology2024
Enhancing organ and vascular contrast in preclinical ultra-low field MRI using superparamagnetic iron oxide nanoparticles.
Article in Communications biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- AI-driven nanomedicine for cancer theranostics.Molecular cancer · 2026Review
- Advancements in nanomaterials for the treatment and management of vascular surgeries: from drug delivery to biomedical implants.Frontiers in bioengineering and biotechnology · 2026Review
- Superparamagnetic iron oxide nanoparticles in clinical applications: current status and future perspectives.EBioMedicine · 2025Review
- Engineering the Colloidal Properties of Iron Oxide Nanoparticles for HighACS applied nano materials · 2025Article
- Current perspectives and global trends of nanotechnology in advanced breast cancer: a bibliometric and visualized analysis.Discover oncology · 2025Article
- Nanoparticles for Cancer Immunotherapy: Innovations and Challenges.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Recovery and Characterization of Tissue Properties from Magnetic Resonance Fingerprinting with Exchange.Journal of imaging · 2025Article
- Refining Lung Cancer Brain Metastasis Models for Spatiotemporal Dynamic Research and Personalized Therapy.Cancers · 2025Review
- Enhanced detection of glioblastoma vasculature with superparamagnetic iron oxide nanoparticles and MRI.Scientific reports · 2025Article
- Nanomaterials in gastric cancer: pioneering precision medicine for diagnosis, therapy, and prevention.Medical oncology (Northwood, London, England) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Superparamagnetic iron oxide nanoparticles (SPIONs) are characterized by their exceptional susceptibility and relaxivity at ultra-low field (ULF) regimes, make them a promising contrast agent (CA) for ULF MRI. Despite their distinct advantages, the translation of these properties into clinically valuable image contrast in ULF MRI remains underexplored. In this study, we investigate the use of SPIONs to generate in vivo MRI contrast at 6.5 mT within the organs and vascular system of rodents. This investigation includes comprehensive SPION characterization and phantom imaging experiments to validate the utility of SPIONs to produce positive image contrast and to facilitate phase-sensitive imaging at ULF. Optimized balanced steady-state free precession (bSSFP) and spoiled gradient echo (SPGR) MRI sequences are used to generate in vivo contrast by leveraging the distinctive properties of SPIONs at ULF. Imaging studies in rodents reveal positive organ contrast attainable in magnitude images, and MRI phase maps can be used to visualize the vascular system. This work demonstrates the effectiveness of SPIONs in enhancing preclinical organ and vascular imaging at ULF; it bridges the gap between the study of the distinctive physical properties of SPIONs and the demonstration of in vivo image contrast.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.